Zobrazeno 1 - 10
of 355
pro vyhledávání: '"Anthony B. El‐Khoueiry"'
Autor:
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 8, Pp 1445-1457 (2023)
Abstract This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC). CheckMate 040 is an open‐label, multicohort, phas
Externí odkaz:
https://doaj.org/article/de9c65b4c41d434c935d3205ca0796a6
Autor:
Anthony B. El-Khoueiry, Tim Meyer, Ann-Lii Cheng, Lorenza Rimassa, Suvajit Sen, Steven Milwee, Robin Kate Kelley, Ghassan K. Abou-Alfa
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progres
Externí odkaz:
https://doaj.org/article/a2e4b8e7964e4b0caa19222250819492
Autor:
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In
Externí odkaz:
https://doaj.org/article/a9aecdc91b464f2abd10eaa8419833fa
Autor:
Amaia Lujambio, Thomas Yau, Lipika Goyal, Andrew X Zhu, Ignacio Melero, Tim F Greten, Ann-Lii Cheng, Bruno Sangro, David J Pinato, Peter R Galle, Ghassan K Abou-Alfa, Austin G Duffy, Anthony B. El-Khoueiry, Richard S Finn, Aiwu Ruth He, Ahmed O Kaseb, Robin Kate Kelley, Riccardo Lencioni, Donna Mabry Hrones, Roberto I Troisi, Andrea Wilson Woods
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC ha
Externí odkaz:
https://doaj.org/article/c395a80c692945e793e9d243958829ae
Autor:
Stephen P. Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry, Andrew X. Zhu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Biliary tract cancers (BTCs) are heterogenous, highly aggressive tumors that harbor a dismal prognosis for which more effective treatments are needed. The role of cancer immunotherapy in BTC remains to be characterized. The tumor microenv
Externí odkaz:
https://doaj.org/article/34c2f66637044bd3a4e8420f05064bd7
Autor:
Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracian, Anthony B. El-Khoueiry, Bruno Sangro, Tarek E. Eldawy, Jordi Bruix, Giovanni Luca Frassineti, Gina M. Vaccaro, Marina Tschaika, Christian Scheffold, Petra Koopmans, Jaclyn Neely, Fabio Piscaglia
Publikováno v:
Journal of Clinical Oncology. 41:1747-1757
PURPOSE To investigate the safety and efficacy of nivolumab plus cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. METHODS In cohort 6 of the multicohort, open-label, phase I/II CheckMate 040 study, patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf11efcf4879d774f339045b67b1d7c5
https://doi.org/10.1200/jco.22.00972
https://doi.org/10.1200/jco.22.00972
Autor:
Sepideh Gholami, Sarah Colby, David P. Horowitz, Katherine A. Guthrie, Edgar Ben-Josef, Anthony B. El-Khoueiry, Charles D. Blanke, Philip A. Philip, Lisa A. Kachnic, Syed A. Ahmad, Flavio G. Rocha
Publikováno v:
Annals of Surgical Oncology. 30:1354-1363
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d97458d6ae5d970db7f83e293a18500
https://doi.org/10.1245/s10434-022-12863-9
https://doi.org/10.1245/s10434-022-12863-9
Autor:
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras
Publikováno v:
Clinical and Translational Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2200786b31ab0f488df7b6acf192a8f9
https://doi.org/10.1111/cts.13544
https://doi.org/10.1111/cts.13544
Autor:
Anthony B. El-Khoueiry, James Clarke, Tobias Neff, Tim Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido-Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak
Publikováno v:
British Journal of Cancer.
Background GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study (NCT03666988) evaluated safety, pharmacokinetics, pharmacodynamics,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52ac42f2063d5215ea193981c4a53135
https://doi.org/10.1038/s41416-023-02276-0
https://doi.org/10.1038/s41416-023-02276-0
Autor:
Dan G. Duda, Andrew X. Zhu, Devalingam Mahalingam, Rebecca Miksad, Alok A. Khorana, Thomas A. Abrams, Gulam A. Manji, Anthony B. El-Khoueiry, Stacey Stein, Jennifer R. Eads, Michael H. Kagey, Michael Schrag, Cynthia Sirard, Lipika Goyal
Purpose:Dickkopf-1 (DKK1) modulates Wnt signaling, promoting tumor growth, metastasis, and immunosuppression. High DKK1 expression has been detected in various tumor types—including biliary tract cancer (BTC)—and is associated with poor prognosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3acc2e0adf4f209458f9bd53a8d231f5
https://doi.org/10.1158/1078-0432.c.6529550.v1
https://doi.org/10.1158/1078-0432.c.6529550.v1
